Advanced FDA engagement for VIASKIN Peanut Patch BLA submission, with strong cash reserves of $174.9 million funding operations into Q3 2027. Net loss widened to $98.0 million for H1 2026, but net loss per share improved due to equity financing.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.